Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.